Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:

NCT ID: NCT05444322 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Start date: July 5, 2022
Phase: Early Phase 1
Study type: Interventional

This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.

NCT ID: NCT05414162 Recruiting - Multiple Myeloma Clinical Trials

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Start date: May 16, 2022
Phase:
Study type: Observational

Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syndrome, which has been described to lead to myocarditis, but larger studies exploring this relationship are currently lacking. In this prospective study, the investigators aim to explore the potential effects of CAR T-cell therapy using cardiac MRI on the heart.

NCT ID: NCT05410418 Recruiting - Follicular Lymphoma Clinical Trials

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Start date: October 24, 2022
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to certain cancerous B cells and then delivers a drug specifically to those cells.

NCT ID: NCT05389293 Recruiting - Lymphoma Clinical Trials

A Study of Mosunetuzumab in People With Follicular Lymphoma

Start date: May 27, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

NCT ID: NCT05387616 Active, not recruiting - Follicular Lymphoma Clinical Trials

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Alternative-C
Start date: October 19, 2020
Phase: Phase 2
Study type: Interventional

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and obinutuzumab in patients with previously untreated follicular lymphoma (FL) and a high tumor burden. Additionally, the combination should be evaluated in terms of secondary efficacy endpoints, treatment compliance, safety and patient-reported symptoms. The study Population includes Patients > 18 years of age with histologically confirmed follicular lymphoma grade 1, 2 or 3A with Ann Arbor Stage III/IV or stage II not suitable for radiotherapy and in need of therapy.

NCT ID: NCT05365659 Recruiting - Clinical trials for Mantle Cell Lymphoma

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Start date: September 5, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

NCT ID: NCT05326308 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

ARIADNE
Start date: April 26, 2022
Phase:
Study type: Observational

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

NCT ID: NCT05284825 Recruiting - Follicular Lymphoma Clinical Trials

A Phase II Trial of Intermediate Radiation Dose For Lymphoma

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma. It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80% (10% total width of the confidence interval) at 3 months. This phase II study will evaluate whether an intermediate dose for follicular lymphoma is associated with excellent response rates while minimizing acute and late toxicity.

NCT ID: NCT05281809 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.